At the news
? NEUTRALIMPACT 3/10 8-K filed Feb 24, 2026 at 16:23 ET
Palvella Therapeutics, Inc. announced preliminary cash, cash equivalents, and marketable securities of approximately $55.9 million as of December 31, 2025. This figure is unaudited, preliminary, and subject to change upon completion of the company's financial closing procedures. No other financial results or operational metrics were disclosed.
- Company reported preliminary cash, cash equivalents, and marketable securities of $55.9 million as of December 31, 2025
- The financial data is preliminary, unaudited, and has not been reviewed by the company's independent auditors
- The final reported amount may differ materially from this estimate
- No revenue, earnings, guidance, or other operational results were disclosed in this filing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access